Genomic and Genetic Characterization of Prostate Tumors Treated with Neoadjuvant Intense Androgen Deprivation Therapy
Demographics (3)
- AGE - Subject age at enrollment (phv00420908.v2.p1)
- SEX - Self-reported sex (phv00420905.v2.p1)
- SEX - Sex (phv00493059.v1.p1)
Disease Events (17)
- AFFECTION_STATUS - Case status of the subject for (phv00420904.v2.p1)
- BASELINE_PSA - Baseline PSA at start of treatment (phv00420906.v2.p1)
- BASELINE_STAGE - Baseline clinical stage (phv00431309.v1.p1)
- BASELINE_VOL - Baseline tumor volume by MRI (phv00431307.v1.p1)
- GLEASON_SCORE - Gleason score of region (phv00420915.v3.p1)
- GLEASON_SCORE - Biopsy Gleason score at start of treatment (phv00420907.v2.p1)
- IS_POST-TREATMENT - Post-treatment status (phv00420918.v3.p1)
- IS_TUMOR - Tumor status (phv00420913.v3.p1)
- LESIONS - Number of MRI-visible lesions (phv00431312.v1.p1)
- PCT_G4_G5 - Percent of LCM tumor Gleason pattern 4 or 5 (phv00431320.v2.p1)
- POST_PSA - PSA at the end of treatment (phv00431306.v1.p1)
- POST_STAGE - Post-treatment clinical stage (phv00431310.v1.p1)
- POST_VOL - Tumor volume by MRI at the end of treatment (phv00431308.v1.p1)
- PREDOMINANT_GLEASON_PATTERN - Predominant Gleason pattern in dissecterd focus (phv00431319.v2.p1)
- PRIMARY_TUMOR_LOCATION - Primary tumor location (phv00420916.v3.p1)
- RCB - Residual cancer burden (pathologic volume) (phv00431311.v1.p1)
- TUMOR_TREATMENT - Type of tumor treatment for sample (phv00420919.v3.p1)
General Health (2)
- BIOPSY - Patient underwent biopsy (phv00431304.v1.p1)
- SURGERY - Surgical procedure for removal of prostate (phv00431305.v1.p1)
Race and Ethnicity (1)
- RACE - Self-reported race (phv00420909.v2.p1)
Other (17)
- ANALYTE_TYPE - Analyte Type (phv00420912.v3.p1)
- BODY_SITE - Body site where sample was collected (phv00420911.v3.p1)
- CONSENT - Consent group as determined by DAC (phv00420898.v2.p1)
- GEO_ACCESSION - GEO accession ID (phv00431314.v2.p1)
- IS_BASELINE - Baseline status (phv00420917.v3.p1)
- IS_CRIBRIFORM - Cribriform morphology (phv00431318.v2.p1)
- IS_DUCTAL - Ductal morphology (phv00431316.v2.p1)
- IS_INTRADUCTAL - Intraductal carcinoma of the prostate (IDC-P) morphology (phv00431317.v2.p1)
- IS_INVASIVE - Invasive morphology (phv00431315.v2.p1)
- ROI - Region of interest (phv00420921.v3.p1)
- SAMPLE_ID - Sample ID (phv00420910.v3.p1)
- SAMPLE_ID - Sample ID (phv00420902.v3.p1)
- SAMPLE_ID - Sample ID (phv00431313.v2.p1)
- SEQUENCING_CENTER - Name of the center which conducted sequencing (phv00420920.v3.p1)
- SUBJECT_ID - Subject ID (phv00420903.v2.p1)
- SUBJECT_ID - Subject ID (phv00420897.v2.p1)
- SUBJECT_ID - Subject ID (phv00420901.v3.p1)